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Other lipid lowering agents
 Do not routinely offer fibrates or anion exchange
resins for primary or secondary prevention, but
consider either of these options if statins are not
tolerated.
 Do not offer nicotinic acid for primary prevention,
but consider it for secondary prevention in people
who cannot tolerate statins.
 Do not offer an anion exchange resin, fibrate, or
nicotinic acid combined with a statin for primary
prevention.
 Consider people with primary hypercholesterolae-
mia for ezetimibe treatment (see the NICE technol-
ogy appraisal on ezetimibe6).
Overcoming barriers
Effectively implementing the recommendations for
primary prevention depends on a structured, systema-
tic approach to identifying people at high risk of
cardiovascular disease. Formal risk assessment will
require good communication with patients and educa-
tion on the meaning of the risk and the benefits and
risks of treatment. Standard models of care should
include advice and support in lifestyle changes for both
primary and secondary prevention. The costing tool
being developed by NICE can be used to estimate
additional costs (www.nice.org.uk/CG67).
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Commentary: Controversies in NICE guidance on lipid
modification for the prevention of cardiovascular disease
Francesco P Cappuccio
The new guidelines from the National Institute for
Health and Clinical Excellence (NICE) on lipid
modification for the prevention of cardiovascular
disease will guide the way we assess cardiovascular
risk and treat lipids, both in primary and in secondary
care.What are thenewaspects, andwhat is it thatmight
spark controversy in this new publication?
Risk assessment
To identify those requiring primary prevention of
cardiovascular disease, the guideline reaffirms the
threshold of a 10 year cardiovascular disease risk
>20% in people aged over 40 years. Its recommenda-
tion of a systematic, rather than opportunistic, risk
assessment is welcome, particularly in primary care.
The new guidelines wisely reaffirm the 1991 Framing-
ham risk score as the score of choice for guiding
primary prevention.
However, they also retain subjective, non evidence-
based adjustments. They advise increasing the risk
estimate by 1.5-2.0 in the presence of premature family
history and by 1.4 in South Asian men, and suggest
clinical judgment for socioeconomic status and severe
obesity. This is a missed opportunity for tackling at
least someof thesematters, suchas the ethnicvariations
in vascular risk, with an evidence based approach.
The Framingham risk does not performwell in ethnic
groups in the United Kingdom,1 and in the absence of
UK cohort studies with significant proportions of black
and ethnic minority groups, a web based tool
(ETHRISK) has been developed for primary care
physicians to allow for such variation.2 This pragmatic
tool is based on a recalibration of existing Framingham
risk scores against survey data on ethnic group risk
factors and disease prevalence compared with the
general population to produce 10 year risk in seven
British black and ethnic minority groups. This could
have been incorporated into most primary care compu-
ter systems. Although the tool is not ideal, its use in
clinical practice would have at least partially prevented
inequalities in cardiovascular disease prevention that are
not easily overcome by subjective judgment.
Lifestyle advice
The approach to lifestyle advice is disappointing. It
perpetuates the belief that, as each listed measure has
been proved to reduce cardiovascular risk, providing
such collective advice will be effective. This is not the
case.3Maybeamore tailored, patient centred approach
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should be used. For instance, focusing on smoking
cessation in apatientwho smokesbut has normalblood
pressureand iswithin idealbodyweightwouldbemore
effective than offering the entire preventive package.
Having said this, the list of effective measures for
primary prevention has a glaring omission: it fails to
mention reducing salt intake as a tool to prevent
cardiovascular disease throughbloodpressure control,
as recently reaffirmed by the World Health
Organization.4 5
Statins and targeting cholesterol levels
The NICE guidelines now recommend the use of
statins for the primary prevention of cardiovascular
disease in adults who have a 10 year cardiovascular
disease risk >20%. They reinforce the preferential use
of simvastatin for primary prevention, as supported by
both intervention trials on cardiovascular end points
and by economic appraisal. Lower dose pravastatin is
recommended as a cheap alternative, but this neglects
compelling data from the randomised controlled
ASCOT trial,6 which used low dose atorvastatin
(10 mg once daily) in high risk patients such as those
targeted by the current guidelines. The study was
stopped earlier than planned (median follow-up 3.
3 years rather than5years) owing to the large reduction
in major cardiovascular events in the intervention
group (36%; 95% confidence interval 17% to 50%).
Finally, for secondary prevention, the guidance
reaffirms the need to increase statin doses until total
cholesterol is <4.0 mmol/l, or low density lipoprotein
cholesterol is <2.0 mmol/l, as in the Joint British
Societies’ JBS 2 guidelines.7 Introducing an “audit
level”of cholesterol and an “ideal target” resembles the
useful approach advocated in the BritishHypertension
Society’s hypertension guidelines.8
Conclusion
Although the new NICE guidance on lipid modifica-
tion comes closer to other guidelines issued by
professional societies, it misses important opportu-
nities for further improvement. It has taken two steps
forward and one back—slow progress but progress.
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Rubber gloves
The manager of the older people’s mental health day
assessment unit was sitting with her feet on the desk, a
broad grin on her face, and a red box in her hand,
telephoning the supplies department. The box had been
unpacked by the unit’s cleaner and was found to contain,
rather than the 200 non-latex gloves she had ordered, 200
non-latex condoms.
The manager finally managed to persuade the supplies
receptionist that these were not really what wewanted and
that the gloves were a more useful alternative, and the
budget didn’t stretch to both. But were they not what we
wanted?
In the emotionally safe environment of the day unit,
we found that many patients had been revealing to us
their sexual worries, and their self perceived sexual
misdemeanours. The number of such discussions had
been increasing to the extent that a training workshop
for staff was organised for us to learn more about
relationship and sexual needs of older people. This
was a thought provoking, though somewhat giggly,
session. It emphasised that we can talk with older people
about sexual matters, and we became better able to
understand the underlying issues when “inappropriate”
sexual activity in people with dementia is reported by
families or carers in homes and sheltered flats.
For a sensible introduction to sex in old age, try the
Help the Aged website, www.helptheaged.org.uk/en-gb/.
Despite its antiquatedname (whoelse uses the term “aged”
these days?) it is extremely forward thinking.
Another myth of activity in old age is that older
people do not use the internet. If you are an older person
interested in sex, in old relationships and new, take
a look at the website—and follow the website’s safety
advice: “If you are starting out on a new sexual
relationship it is important, if a little unromantic, to
think about your sexual health. Not having to worry
about unwanted pregnancies does not mean that you
should throw caution to the wind: sexually transmitted
diseases are on the increase in the UK, and it’s not all
down to young people.”
Should we have kept the condoms?
Claire Hilton consultant
Mental Health Service for Older Adults,
Northwick Park Hospital, Harrow
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